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Abstract
Introduction: In order to improve diagnosis procedure by public health service, an organizational solution called Rapid Oncological 
Path has been introduced. The introduction of this program caused criticism of the medical community, and state control autho-
rities showed irregularities in its functioning in medical clinics. Its aim was to assess this process among lung cancer patients 
hospitalized in in our center, in the period of 9 months.
Material and methods: After the analysis of imaging tests, the patients were qualified for invasive tests (bronchoscopy, EBUS). 
Patients with histopathological diagnosis of NSCLC were subjected to molecular diagnostics. After completing the diagnosis and 
establishing the final diagnosis, the patient’s forfeiture was presented at the clinical meeting.
Results: The analysis involved 209 patients who had a an oncological card (DILO) issued. 156 patients were diagnosed with lung 
cancer and qualified for the consulate. Among the histopathological types, NSCLC dominated — 80%. SCLC was 17% of the types. By 
the decision made on medical case conference, 135 patients have been qualified for casual treatment, among others 12% surgical tre-
atment; 47% chemotherapy, 18% radiotherapy; 8% chemo-radiotherapy. An average waiting time for diagnosis process to begin, after 
DILO card has been issued was 16.33 (± 18.78) days, an average hospitalization and diagnosis time was 9.16 (± 6.61) days. Around 
31.3 (± 14.93) days on average have passed from the start of diagnostical hospitalization until beginning of the causal treatment.
Conclusions: In a multi-specialist center, it is possible to develop a care model for lung cancer patients, consistent with Rapid 
Oncological Path.
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Introduction 
Lung cancer is the most common type of 
tumour (1.2 million incidences per year). It occurs 
mainly among men; the highest estimated rate of 
occurrence is noted in Central and Eastern Europe 
(53.3/100,000) and in East Asia (50.4/100,000) [1]. 
In highly developed countries, lung cancer is the 
main cause of death among oncological patients [2]. 
In Poland, 21 556 people were diagnosed with 
lung cancer in 2013. It amounts to 14% of all 
malignant tumours noted in the country, making 
it the most commonly diagnosed oncological 
disease in Poland.
Cancerous diseases constitute the second 
most common cause of death among Polish pe-
ople. Among these, lung cancer is ranked in the 
first place (24% deaths of oncological causes), 
right before colorectal cancer (7.6%) and breast 
cancer (6.2%). It is also noticeable that death rate 
among patients of both sexes in Poland exceeds 
the average rate of all European Union countries 
(20.6% for women and 56.4% for men). A stan-
dardised rate for 5- year survival of lung cancer 
throughout last decade is up to 13.4% [3].
The effectiveness of lung cancer therapy 
depends mainly on the primary clinical stage of 
the disease as well as on histopathological type 
of the tumour. In Poland, lung cancer is rarely 
recognised at an early stage. 80% of patients have 
been diagnosed at the 3rd or 4th stage of the disease.
In order to improve the diagnostic procedure 
and start the treatment, the Rapid Oncological 
Path has been introduced. It is an organisational 
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solution that aims at leading the patient through 
respective diagnosis and treatment stages. It is 
dedicated to all patients that are suspected to 
have a malignant tumour or are diagnosed with 
it [4]. This programme has been launched on 
January 1st, 2015.
The introduction of amendments to the Act 
on healthcare services financed from public funds 
and certain other acts (Journal of Laws 2018 item 
1532) [5] (introducing the oncology and queue 
package) caused a number of comments and do-
ubts in the medical environment. The top state 
audit body (NIK — the Supreme Audit Office), 
during the activities checking the functioning of 
the programme in healthcare facilities, pointed 
out numerous errors [6, 7].
The oncological package has been introduced 
in the Department of Internal Diseases, Pneumo-
logy, Allergology and Clinical Immunology of the 
Military Institute of Medicine on July 1st, 2016.
It was focused on the assessment of rapid 
oncological diagnosis procedures in frames of 
“Oncological Package” among lung cancer pa-
tients who were hospitalised in the Department 
between July 1st, 2016 and March 3rd, 2018.
Material and methods
During the research period, a group of 209 
patients has been diagnosed, including 136 men 
and 73 women, 68 ± 10 of age (SD).
CT or analysis of provided results has been 
performed for each patient. Further diagnosis 
was implemented based on those results, aiming 
at a collection of tissue material. It was gath-
ered by invasive diagnostic methods: forceps 
biopsy via bronchoscopy, transbronchial biopsy 
during endobronchial ultrasound (EBUS); lung 
biopsy monitored by USG or CT. Molecular 
diagnosis has been performed on patients with 
histopathological recognition of non-small cell 
lung cancer (adenocarcinoma, carcinoma NOS 
(not otherwise specified), large cell carcinoma 
(LCC): the presence of EGFR mutations (epi-
dermal growth factor receptor); rearrangement 
of the ALK gene (anaplastic lymphoma kinase) 
and in the case of the negative ones, test for 
the evaluation of PD-L1 expression [8]. Molec-
ular studies were performed at the Department 
of Genetics and Clinical Immunology at the 
National Institute of Tuberculosis and Lung 
Diseases in Warsaw.
Once the diagnosis was finished and final 
recognition established, a particular case has been 
presented during a clinical assembly (medical 
case conference, interdisciplinary group of spe-
cialists consisting of an oncologist, radiotherapist, 
cardiothoracic surgeon, radiologist, pneumolo-
gist) in order to define further treatment.
Basic statistical descriptive methods deter-
mining average values and standard deviation 
(SD) for patients’ age and specific dates of re-
spective diagnosis stages, have been used in 
the analysis. Moreover, a percentage value for 
each histopathological type of cancer has been 
established.
The survival rate based on the disease’s stage 
and type of  treatment applied has been deter-
mined with the Kaplan-Meier estimator. Statisti-
cal significance of differences between the groups 
in survival was calculated with the log-rank test. 
In our analysis, p-value below 0.05 was a cutoff 
for statistical significance.
Descriptive statistics and testing of hypothe-
ses were used for the analysis using STATISTICA 
software (StatSoft Inc,version 12).
Results
Two hundred and nine patients with diag-
nosis and an oncological treatment card (DILO) 
have been analysed. One hundred twenty and 
two cards have been issued by family doctors. 
Nine of the cards have been issued by specialists 
from the Pulmonology Clinic and 79 of them in 
the hospital.
For 53 patients, the card has been closed due 
to: death (13 cases); normal medical image of CT 
of chest (10 cases); focal abnormalities without 
any symptoms of tumour (29 cases); congenital 
defect (pulmonary sequestration) (1 case).
One hundred fifty and six patients have been 
diagnosed with lung cancer and qualified for 
medical case conference (including 102 men 69 
± 10 of age [SD] and 54 women 68 ± 8 of age SD).
Non-small cell lung cancer (NSCLC) was the 
most common of all histopathological types — 
80% (124 patients). Small cell lung cancer (SCLC) 
type constituted 17% of all the 27 patients. The 
remaining 1% of histopathological types are: 
metastatic carcinoma — anaplastic breast cancer 
(2 cases); mixed cancer — NSCLC and SCLC (2 
cases) and undefined (1 case).
Based on numerous clinical data, lung can-
cer patients have been defined and assigned to 
specific disease stages:
—  1st stage: 17 patients (11%),
—  2nd stage: 12 patients (8%),
—  3rd stage: 57 patients (36%),
—  4th stage: 70 patients (45%).
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DIAGNOSIS TREATMENTSUSPICION
Waiting time of
16.33 ± 18.76 days
Hospitalization 
of 9.16 ± 6.61 days
Waiting time for
 the oncology consilium
of 10.61 ± 8.39 days
Waiting time 
for treatment
of 11.81 
± 12.79 days
31.3 ± 14.93 days
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Figure 2. Estimated survival curves for stage I, stage II, stage III and stage IV patients with lung cancer (p-value 0.00001, log-rank test)
Histological subtypes of lung cancer of the 
studied group are shown in Table 1.
A molecular lung cancer diagnosis for EGFR 
gene mutation, rearrangement of ALK gene and 
expression of PD-L1 have been performed. In none 
of the above cases was the mutation confirmed.
135 patients have been qualified for casual 
treatment, basing on the decision made at the 
medical case conference. Among others:
— 19 patients for a surgery (12%),
— 74 patients for chemotherapy (19%),
— 29 patients radiotherapy (19%),
— 13 patients chemo-radiotherapy (8%).
Twenty one subjects have been disqualified 
from casual treatment and qualified for palliative 
therapy instead.
An average (SD) waiting time for the diagnosis 
process to begin, after DILO card has been issued 
was 16.33 ± 18.78 days. The average (SD) hospi-
talisation and diagnosis time was 9.16 ± 6.61 days. 
Around 31.3 ± 14.93 days on average (SD) have 
passed from the start of diagnostic hospitalisation 
until the beginning of the causal treatment (Fig. 1).
Patients’ survival time, based on the disease 
stage and applied treatment, has been analysed: 
survival time from the moment of diagnosis: me-
Table 1. Histological subtypes of lung cancer of the studied group
Lp. Histological subtypes of lung cancer Number of cases (% of total)
1 Squamous cell carcinoma 61 (49%)
2 Adenocarcinoma 48 (39%)
3 Non-small cell cancer — unspecified 6 (5%)
4 Carcinoma NOS (not otherwise specified) 5 (4%)
5 Neuroendocrine carcinoma 4 (3%)
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Figure 3. Estimated survival curves for patients with lung cancer depending on the type of treatment (p-value 0.0003, log-rank test)
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Figure 4. Gender-specific survival probability curves for non-small cell lung (p-value 0.029, log-rank test)
dian 118 days, IQR 223.5. The longest survival 
time was observed in case of 1st stage patients, and 
the most effective type of treatment was a surge-
ry: average survival median 340 days; IQR 250. 
Median survival for women was 144.5 days (IQR 
257) and for men 109.5 days (IQR 193). Estimated 
1-year survival time for men: 29.34%, for women: 
46.06% (Figs 2–4).
Discussion and conclusions 
It has been estimated, taking demographic 
processes into consideration exclusively, that 
between 2016 and 2029 the number of patients 
diagnosed with lung cancer will increase in Po-
land from 180 300 to 213 100 (18%). The most 
rapid growth will be observed in wielkopolskie 
voivodship [10] (22.3%), pomorskie (22.3%), 
podkarpackie (22.2%) and małopolskie (21.8%). 
The smallest growth, on the other hand, will be 
noticed in łódzkie (11.6%) and śląskie (13.4%) 
voivodships [9]. Malignant lung tumour will be 
the most common type of cancer in 2029. Simul-
taneously, the costs of treatment of lung cancer 
patients grow methodically. Between 2005 and 
2014, the expenses of the National’s Health Fund 
(NFZ) on patients starting their lung cancer treat-
ment had been growing. In 2015, NFZ spent more 
than 48.1 million PLN for medicine packages for 
non- small lung cancer patients, which consti-
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tuted only 3.74% of expenses for all medicine 
packages for oncological diseases [10].
Introducing the DILO card by the legislator 
was aimed to improving conditions of patients 
suspected of cancer or diagnosed with it within 
the healthcare system. Thanks to the card, the 
diagnosis procedure and oncological treatment 
are meant to be clearly defined and the patient 
is entitled to complex medical care during every 
stage of the disease [11].
Within this medical package, maximum 
waiting time in terms of each stage of patients’ 
treatment has been defined (35 days for initial 
diagnosis, 28 days for further one, 14 days for 
medical case conference and beginning of the 
treatment) [11].
Analysis of the diagnosis and treatment 
conducted by the Watch Health Care Foundation 
(WHC) assessed that for patients with a DILO card, 
it takes approximately 8.7 weeks (2.2 months) be-
tween the moment the cancer has been recognised 
and the beginning of the palliative radiotherapy. 
In the previously researched period (September 
2016), time designated for initial and further di-
agnosis for patients with a DILO card was approx-
imately 5.8 weeks, which is a 2.9-week decrease. 
14 days is a period defined by the Ministry of 
Health as time for performing the first surgery 
since the medical case conference. In case of lung 
cancer patients with a DILO card, 2.7 weeks is 
the waiting time for the surgery, and molecular 
disease-specific treatment takes up about 1 week. 
Overall waiting time does not exceed the limit of 
7 weeks defined by the Ministry of Health [12].
Within the analysed group, an average (SD) 
time between the beginning of hospitalisation 
and the beginning of the casual treatment (on-
cological treatment) was determined as 31.3 ± 
14.93 days (4.5 weeks). Once again waiting time 
does not exceed the limit of 7 weeks defined by 
the Ministry of Health.
NFZ data have shown that in 2017 there 
were 9589 institutions providing medical services 
based on a DILO card. A high number of available 
facilities such as this increases the accessibility of 
these kind of services, but at the same time, it dis-
perses diagnosis process and treatment between 
numerous facilities. It makes proper monitoring 
of service quality and coordination of the process 
more complicated [10].
Correlation of time limits within the onco-
logical package adjusted to fit with the patient’s 
actual path; shows why meeting the deadlines 
of each stage defined by the oncological package 
regulations does not necessarily have to result in 
shortening a real waiting time from suspicion to 
treatment. Within the package, keeping the time 
limits is mandatory only with regard to specific 
stages of diagnosis and treatment. Within those 
limits, time is measured from the moment the 
patient was placed on the waiting list. The time 
between stages is not taken into consideration. 
This restriction also refers to the beginning of 
the “path”. It means that some time might pass 
from the moment the card has been issued by 
the specialist (in case of disease suspicion) to 
the moment the patient is entered on the initial 
diagnosis waiting list. The beginning of the tre-
atment within the oncological package does not 
have to equal a surgery, application of medica-
tions or radiotherapy. This package also includes 
a medical consultation — some other operations 
might be performed then, among others: a con-
sultation with further preparation or treatment 
planning [13].
A full-time control on every stage was per-
formed within a group of patients diagnosed and 
treated in the Military Institute of Medicine. It re-
sulted in a realisation of all diagnostic procedures 
as well as the implementation of casual treatment 
in a significantly shorter period of time than the 
one originally estimated (4.5 weeks). It indicates 
the need for development of multi-speciality 
cancer centres and their promotion in the public 
healthcare system.
An alternative solution is the introduction 
of coordination between service providers who 
execute only some parts of the diagnostic “path” 
by, e.g., imposing obligation to lead the patient 
through the whole “path” of diagnosis. It is also 
essential to take responsibility for oncological 
patients in case any treatment complications 
occur. Those patients are most often left on their 
own, and it is difficult for them to function in the 
healthcare system.
Implemented diagnosis and treatment must 
be also analysed in terms of their effectiveness. 
One of the parameters that might be applied is ba-
sed on survival rate or number of repeated hospita-
lisations, due to ineffective diagnosis (neoplasms 
of uncertain behaviour and unspecified sites of 
middle ear, respiratory system and chest organs). 
In 2017, in the study authors’ center, 19% of onco-
logical patients have been repeatedly hospitalised 
due to ineffective lung cancer diagnosis (Table 2).
The rate of repeated hospitalisation in Poland 
differs depending on the region. It happens most 
often in wielkopolskie voivodship (49%) and 
the least often – in kujawsko-pomorskie (20%). 
On average, 32% of patients with suspicion or 
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Figure 5. Indicators of 1-year relative survival in patients with lung cancer in Poland [3]
diagnosis of lung cancer has been hospitalised 
twice in 2014 [10].
Among patients who have been diagnosed with 
lung cancer between 2000 and 2001, 1-year surviv-
al rate was 34.7% for men and 41.6% for women. 
Between 2003 and 2005 this rate was at the level 
of 34.9% for men and 41.7% for women (Fig. 5).
In the examined group, the tendency was 
similar — survival rate was higher for women 
and lower for men.
Lung cancer is a growing problem not only in 
Poland. The risk of cancer can be reduced by in-
fluencing carcinogenic factors that can be modified. 
The most influential factor is smoking. Smokers are 
about 15–30 times more prone to get a cancer [14]. 
Third-person exposure (passive smoking) also in-
creases the risk of lung cancer [15]. Implementation 
of prevention actions (banning advertisements, 
raising cigarette prices) that result in decrease of 
smoking rate, especially among the youth, could 
influence society’s health [14]. Also, damaging 
habits can also be substituted with less harmful 
ones (e.g. replacing cigarettes with e-cigarette) [16].
Considering worsening air quality (heavy 
metals) and its documented effect on respiratory 
system diseases, including its impact on carcino-
genesis, it is important to take up actions aimed at 
the protection of the environment and limitation 
of air pollution [16, 17].
Despite the fact that the oncological package 
has existed for 3 years now, it is still subject to 
varied opinions. The Ministry of Health claims 
it has improved diagnosis and treatment proce-
dures, but the medical community expresses its 
doubts and indicates bureaucracy problems as 
well as the fact that the situation of patients has 
not been improved [18, 19].
The authors’ experience corresponds with the 
Supreme Audit Office’s report and shows that it is 
possible to develop a care model for lung cancer 
patients, consistent with the Rapid Oncological 
Path. Also, making treatment more personalised 
will give patients a sense of security at every stage 
of the disease [7].
Conflict of interest
The authors declare no conflict of interest.
References:
1. Estimated Cancer Incidence, Mortality and Prevalence World-
wide in 2012. GLOBOCAN 2012. http://http://globocan.iarc.fr/
Pages/fact_sheets_cancer.aspx (10.01.2019).
2. World Health Organization; Global Status Report on noncom-
municable diseases. Geneva, WHO 2014.
Table 2. Analysis of hospitalization codes
CD-10 Diagnosis Codes 2015 2016 2017
C34 49 50 105
D38 301 232 200
Sum 350 282 305
Second hospitalizations 81 88 59
Advances in Respiratory Medicine 2019, vol. 87, no. 2, pages 96–102 
102 www.journals.viamedica.pl
3. Wojciechowska U., Didkowska J. Zachorowania i  zgony na 
nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, 
Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie. 
http://onkologia.org.pl/raporty/ (22.02.2019 ).
4. Ministerstwo Zdrowia. http://mz.gov.pl (22.02.2019 ).
5. Internetowy System Aktów Prawnych. http://prawo.sejm.gov.
pl/ (22.02.2019 ).
6. Matczak M, Zalasiński T, Czarnuch M. Raport regulacyjny 
w sprawie oceny konstytucyjności ustawy z dnia 22 lipca 2014 
r. o zmianie ustawy o świadczeniach opieki zdrowotnej finan-
sowanych ze środków publicznych oraz niektórych innych 
ustaw (wprowadzającej tzw. pakiet onkologiczny i kolejkowy). 
https://www.nil.org.pl/ (22.02.2019).
7. Najwyższa Izba Kontroli; Informacja o  wynikach kontroli. 
Przygotowanie i wdrożenie pakietu onkologicznego. NIK 2017. 
https://www.nik.gov.pl/kontrole/P/16/057/LPO (20.02.2019).
8. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular 
testing guideline for the selection of lung cancer patients for 
treatment with targeted tyrosine kinase inhibitors: guideline 
from the college of american pathologists, the  international 
association for the study of lung cancer, and the association 
for molecular pathology. J Thorac Oncol. 2018; 13(3): 323–358, 
doi: 10.1016/j.jtho.2017.12.001, indexed in Pubmed: 29396253.
9. Mapa potrzeb zdrowotnych w  zakresie onkologii dla Polski. 
http://www.mpz.mz.gov.pl/mapy-potrzeb-zdrowotnych-w-za-
kresie-onkologii/ (12.12.2018).
10. Chorostowska-Wynimko J. (red.). Strategia walki z  rakiem 
płuca. Instytut Gruźlicy i  Chorób Płuc, Polska Grupa Raka 
Płuca, Polska Liga Walki z Rakiem. https://ligawalkizrakiem.
pl (21.01.2019).
11. Szybka Terapia Onkologiczna, Ministerstwo Zdrowia. http://
pakietonkologiczny.gov.pl/ (11.12.2018).
12. OnkoBarometr Fundacji Watch Health Care nr 9/1/02/2017. 
www.korektorzdrowia.pl (11.12.2018).
13. Analiza czasu oczekiwania pacjentów na diagnozę i leczenie 
chorób nowotworowych w  Polsce. http://onkologia2025.pl/ 
(11.12.2018 ).
14. Gibson GJ, Loddenkemper R, Lundbäck Bo, et al. Respi-
ratory health and disease in Europe: the new European 
Lung White Book. Eur Respir J. 2013; 42(3): 559–563, doi: 
10.1183/09031936.00105513, indexed in Pubmed: 24000245.
15. Office on Smoking and Health (US). The health consequences 
of involuntary exposure to tobacco smoke: a  report of the 
surgeon general. Atlanta (GA): Centers for Disease Control and 
Prevention (US); 2006. Indexed in PubMed 20669524.
16. Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung 
cancer worldwide. Eur Respir J. 2016; 48(3): 889–902, doi: 
10.1183/13993003.00359-2016, indexed in Pubmed: 27174888.
17. Chen CY, Peng HC, Chen YY, et al. Association of environ-
mental heavy metals exposure and lung cancer incidence and 
prognosis. 11.1 Lung Cancer. 2016, doi: 10.1183/13993003.
congress-2016.pa2805.
18. Stanisławek A. Karta DiLO jednym z  większych osiągnięć 
w onkologii. https://www.mp.pl/kurier/ (12.12.2018).
19. Wojtyła A. Pakiet onkologiczny to chybiony pomysł. https://
www.mp.pl/kurier (12.12.2018).
